LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 33

Search options

  1. Article ; Online: Venetoclax in acute myeloid leukemia.

    Bruzzese, Antonella / Martino, Enrica Antonia / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on investigational drugs

    2023  Volume 32, Issue 4, Page(s) 271–276

    MeSH term(s) Humans ; Leukemia, Myeloid, Acute/drug therapy ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols
    Chemical Substances venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides
    Language English
    Publishing date 2023-03-23
    Publishing country England
    Document type Editorial
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2023.2193679
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on investigational drugs

    2024  Volume 33, Issue 2, Page(s) 73–77

    MeSH term(s) Humans ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/pathology ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Proto-Oncogene Proteins c-bcl-2
    Chemical Substances Antineoplastic Agents ; Proto-Oncogene Proteins c-bcl-2 ; BCL2 protein, human
    Language English
    Publishing date 2024-01-26
    Publishing country England
    Document type Editorial
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2024.2309873
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3739: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Momelotinib in myelofibrosis.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Zimbo, Annamaria / Fragliasso, Valentina / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2024  , Page(s) 1–8

    Abstract: Introduction: Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, ...

    Abstract Introduction: Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence, and even worsening anemia remains a significant challenge, leading usually to treatment discontinuation.
    Areas covered: This review focuses on Momelotinib (MMB), a unique JAK inhibitor that has shown promise in MF treatment, particularly in improving anemia. MMB inhibits type 1 kinase activin A receptor or activin receptor-like kinase-2 (ACVR1/ALK2), with consequent rebalancing of the SMAD pathways and reduced transcription of hepcidin. Moreover, it seems that MMB could reduce the serum levels of several inflammatory cytokines responsible for anemia. Clinical trials have demonstrated MMB's efficacy in reducing spleen size, alleviating symptoms, and improving anemia, with a favorable safety profile compared to other JAK inhibitors, both in treatment-naïve and in pre-treated patients.
    Expert opinion: Due to its mechanism of action, MMB represents a valuable therapeutic option in MF, addressing the clinical challenge of anemia and potentially improving outcomes for patients with hematologic malignancies. Ongoing research explores MMB's potential in acute myeloid leukemia and combination therapies.
    Language English
    Publishing date 2024-04-18
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2024.2343780
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Selinexor in multiple myeloma.

    Martino, Enrica Antonia / Vigna, Ernesto / Bruzzese, Antonella / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Zimbo, Annamaria / Torricelli, Federica / Neri, Antonino / Morabito, Fortunato / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2024  Volume 25, Issue 4, Page(s) 421–434

    Abstract: Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).: Areas covered: This article provides a review of selinexor, with a focus on ... ...

    Abstract Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).
    Areas covered: This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progressionfree survival (mPFS). Selinexor's versatility is evident across various combinations, including carfilzomibdexamethasone (XKd), lenalidomidedexamethasone (XRd), and pomalidomidedexamethasone (XPd), with efficacy observed even in tripleclass refractory and highrisk patient populations. However, challenges, including resistance mechanisms and adverse events, necessitate careful management. Realworld evidence also underscores selinexor's effectiveness in RRMM, though dose adjustments and supportive measures remain crucial. Ongoing trials are exploring selinexor in diverse combinations and settings, including pomalidomidenaïve patients and postautologous stem cell transplant (ASCT) maintenance.
    Expert opinion: The evolving landscape of selinexor's role in the sequencing of treatment for RRMM, its potential in highrisk patients, including those with extramedullary disease, as revealed in the most recent international meetings, and ongoing investigations signal a dynamic era in myeloma therapeutics. Selinexor emerges as a pivotal component in multidrug strategies and innovative combinations.
    MeSH term(s) Multiple Myeloma/drug therapy ; Humans ; Hydrazines/therapeutic use ; Hydrazines/adverse effects ; Triazoles/therapeutic use ; Triazoles/adverse effects ; Karyopherins/antagonists & inhibitors ; Exportin 1 Protein ; Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Progression-Free Survival
    Chemical Substances selinexor (31TZ62FO8F) ; Hydrazines ; Triazoles ; Karyopherins ; Exportin 1 Protein ; Receptors, Cytoplasmic and Nuclear ; Antineoplastic Agents
    Language English
    Publishing date 2024-03-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2024.2333376
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Ivosidenib in acute myeloid leukemia.

    Bruzzese, Antonella / Labanca, Caterina / Martino, Enrica Antonia / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Imovilli, Annalisa / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2024  Volume 24, Issue 18, Page(s) 2093–2100

    Abstract: Introduction: Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the ... ...

    Abstract Introduction: Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the introduction of hypomethylating agents and small molecules.Bcl2 inhibitor venetoclax, Fms-like tyrosine kinase 3 (FLT3) inhibitors such as midostaurin and gilteritinib, and isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) inhibitors ivosidenib and enasidenib, as well as hedgehog (HH) pathway inhibitor glasdegib represented a significant step forward in AML therapeutic armamentarium. Smoothened (SMO) inhibitor in combination with low-dose cytarabine marks a recent milestone.
    Areas covered: Ivosidenib, the first-in-class, selective, allosteric IDH1R132 inhibitor, showed the capability to induce
    Expert opinion: The identified ivosidenib's strengths, including its remarkable safety record and ability to yield positive therapeutic outcomes, position it as an ideal partner for both classic chemotherapy and biological treatments, i.e. hypometilant agents and/or venetoclax. Further studies are warranted to explore strategies for overcoming the occurrence of ivosidenib resistance.
    MeSH term(s) Humans ; Hedgehog Proteins ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Pyridines/adverse effects ; Antineoplastic Agents/adverse effects ; Mutation
    Chemical Substances ivosidenib (Q2PCN8MAM6) ; venetoclax (N54AIC43PW) ; Hedgehog Proteins ; Pyridines ; Antineoplastic Agents
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2272659
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.

    Bruzzese, Antonella / Martino, Enrica Antonia / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Capodanno, Isabella / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    European journal of haematology

    2024  Volume 112, Issue 6, Page(s) 860–869

    Abstract: Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly half of MDS patients carry cytogenetic alterations, with ...

    Abstract Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly half of MDS patients carry cytogenetic alterations, with del(5q) being the most prevalent. Since its first description, del(5q) was consistently correlated with a typical clinical phenotype marked by anemia, thrombocytosis, and a low risk of evolving into acute leukemia. Presently, the World Health Organization (WHO) classification of myeloid neoplasms recognizes a specific subtype of MDS known as "myelodysplastic neoplasm with low blast and isolated del(5q)" identified by the sole presence of 5q deletion or in combination with one other abnormality excluding -7/del(7q). Several studies have sought to unravel the biological processes triggered by del(5q) in the development of MDS, revealing the involvement of various genes localized in specific regions of chromosome 5 referred to as common deleted regions (CDR). This intricate biological landscape makes the MDS cells with del(5q) exceptionally sensitive to lenalidomide. Several studies have confirmed the efficacy of lenalidomide in this context. Regrettably, the response to lenalidomide is not conclusive, prompting ongoing research into biological mechanisms that drive patients toward leukemia and strategies to circumvent lenalidomide resistance and disease progression.
    MeSH term(s) Humans ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/therapy ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/etiology ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Lenalidomide/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology
    Chemical Substances Lenalidomide (F0P408N6V4) ; Antineoplastic Agents
    Language English
    Publishing date 2024-01-31
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.14181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.

    Bruzzese, Antonella / Vigna, Ernesto / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Stanzione, Gaia / Zimbo, Annamaria / Lugli, Elisabetta / Neri, Antonino / Morabito, Fortunato / Gentile, Massimo

    Expert review of hematology

    2024  

    Abstract: Introduction: Acute myeloid leukemia (AML) encompasses a heterogeneous group of aggressive myeloid malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent, accounting for approximately 25-30% of adult patients. The presence of this ...

    Abstract Introduction: Acute myeloid leukemia (AML) encompasses a heterogeneous group of aggressive myeloid malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent, accounting for approximately 25-30% of adult patients. The presence of this mutation is related to a dismal prognosis and high relapse rates. In the lasts years many FLT3 inhibitors have been developed.
    Areas covered: This review provides a comprehensive overview of FLT3
    Expert opinion: In addition, the review discusses the emergence of drug resistance and the need for a nuanced approaches in treating patients who are ineligible for or resistant to intensive chemotherapy. Specifically, it explores the historical context of FLT3 inhibitors (FLT3Is) and their impact on treatment outcomes, emphasizing the pivotal role of midostaurin, as well as gilteritinib and quizartinib, and providing detailed insights into ongoing trials exploring the safety and efficacy of novel triplet combinations involving FLT3Is in different AML settings.
    Language English
    Publishing date 2024-05-15
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1080/17474086.2024.2356258
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6943: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Peripherally inserted central catheter in patients with acute myeloid leukemia: incidence and risk factors for premature removal.

    Bruzzese, Antonella / Chistolini, Antonio / Morano, Salvatore Giacomo / Fegatelli, Danilo Alunni / Micozzi, Alessandra

    Leukemia & lymphoma

    2020  Volume 61, Issue 9, Page(s) 2265–2267

    MeSH term(s) Catheterization, Central Venous/adverse effects ; Catheterization, Peripheral ; Catheters ; Catheters, Indwelling ; Humans ; Incidence ; Leukemia, Myeloid, Acute/epidemiology ; Leukemia, Myeloid, Acute/therapy ; Risk Factors
    Language English
    Publishing date 2020-05-21
    Publishing country United States
    Document type Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1762880
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Belantamab mafodotin in multiple myeloma.

    Martino, Enrica Antonia / Bruzzese, Antonella / Iaccino, Enrico / Labanca, Caterina / Mendicino, Francesco / Mimmi, Selena / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on biological therapy

    2023  Volume 23, Issue 11, Page(s) 1043–1047

    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Antibodies, Monoclonal, Humanized
    Chemical Substances belantamab mafodotin (DB1041CXDG) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2023-05-27
    Publishing country England
    Document type Editorial
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2023.2218543
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Isatuximab in multiple myeloma.

    Martino, Enrica Antonia / Bruzzese, Antonella / Iaccino, Enrico / Mendicino, Francesco / Mimmi, Selena / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on biological therapy

    2023  Volume 23, Issue 4, Page(s) 315–318

    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal/adverse effects ; Dexamethasone/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols
    Chemical Substances isatuximab (R30772KCU0) ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal ; Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2023-03-24
    Publishing country England
    Document type Editorial
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2023.2193289
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top